{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:32:47Z","timestamp":1776738767940,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacl.2025.05.021","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:36:18Z","timestamp":1748979378000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-069X","authenticated-orcid":false,"given":"Shyann","family":"Hang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-0522","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-217X","authenticated-orcid":false,"given":"Zahra","family":"Taboun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.05.021_bib0001","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-021-01517-6","article-title":"Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study","volume":"20","author":"Berberich","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.05.021_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2025.05.021_bib0003","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.jacl.2025.05.021_bib0004","first-page":"00066","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"S1933-2874","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.021_bib0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jacl.2025.05.021_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol."},{"issue":"5","key":"10.1016\/j.jacl.2025.05.021_bib0007","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacl.2021.07.004","article-title":"Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2","volume":"15","author":"Lazarte","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.021_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2350-7-3","article-title":"Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)","volume":"7","author":"Francis","year":"2006","journal-title":"BMC Med Genet"},{"issue":"5","key":"10.1016\/j.jacl.2025.05.021_bib0009","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2006-1807","article-title":"Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma","volume":"92","author":"Monajemi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.05.021_bib0010","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1194\/jlr.P025437","article-title":"Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPAR\u03b3 deficiency","volume":"53","author":"Campeau","year":"2012","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.jacl.2025.05.021_bib0011","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14310\/horm.2002.1585","article-title":"Familial partial lipodystrophy type 3: a new mutation on the PPARG gene","volume":"14","author":"Lau","year":"2015","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.jacl.2025.05.021_bib0012","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6065\/apem.2142056.028","article-title":"Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes","volume":"26","author":"Gutierrez Alvarez","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jacl.2025.05.021_bib0013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacl.2021.03.006","article-title":"Novel PPARG mutation in multiple family members with chylomicronemia","volume":"15","author":"Glodowski","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.021_bib0014","first-page":"21","article-title":"Rapid response to leptin therapy in a FPLD patient with a novel PPARG missense variant","volume":"2021","author":"Melzer","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"10.1016\/j.jacl.2025.05.021_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684182","article-title":"Case report: metreleptin treatment in a patient with a novel mutation for familial partial lipodystrophy type 3, presenting with uncontrolled diabetes and insulin resistance","volume":"12","author":"Lambadiari","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.021_bib0016","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6065\/apem.2142056.028","article-title":"Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes","volume":"26","author":"Gutierrez Alvarez","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jacl.2025.05.021_bib0017","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/diagnostics12051122","article-title":"Familial partial lipodystrophy-literature review and report of a novel variant in PPARG expanding the spectrum of disease-causing alterations in FPLD3","volume":"12","author":"Rutkowska","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"22","key":"10.1016\/j.jacl.2025.05.021_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212060","article-title":"Genomic and bioinformatics analysis of familial partial lipodystrophy type 3 identified in a patient with novel PPAR\u03b3 mutation and robust response to pioglitazone","volume":"25","author":"Hummadi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.021_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00000441-199504000-00005","article-title":"Successful outcome in severe pregnancy-associated hyperlipemia: a case report and literature review","volume":"309","author":"Hsia","year":"1995","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.jacl.2025.05.021_bib0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1194\/jlr.R700004-JLR200","article-title":"Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism","volume":"48","author":"Hegele","year":"2007","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.jacl.2025.05.021_bib0021","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/dme.13061","article-title":"Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -\u03b3 (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 lamin A\/C (LMNA) mutations","volume":"33","author":"Demir","year":"2016","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.05.021_bib0022","doi-asserted-by":"crossref","first-page":"bvac155","DOI":"10.1210\/jendso\/bvac155","article-title":"Phenotypic differences among familial partial lipodystrophy due to LMNA or PPARG variants","volume":"6","author":"Vasandani","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jacl.2025.05.021_bib0023","first-page":"dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","author":"Spagnuolo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.021_bib0024","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacl.2022.11.007","article-title":"The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.021_bib0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacl.2023.08.003","article-title":"Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.021_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.021_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jacl.2020.01.003","article-title":"The polygenic nature of mild-to-moderate hypertriglyceridemia","volume":"14","author":"Dron","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.021_bib0028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-020-0669-2","article-title":"Six years\u2019 experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias","volume":"13","author":"Dron","year":"2020","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jacl.2025.05.021_bib0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.021_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2025.05.021_bib0031","first-page":"405","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"7","key":"10.1016\/j.jacl.2025.05.021_bib0033","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1194\/jlr.R700004-JLR200","article-title":"Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism","volume":"48","author":"Hegele","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2025.05.021_bib0034","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2025.05.021_bib0032","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MED.0000000000000695","article-title":"Advances in the care of lipodystrophies","volume":"29","author":"Shamsudeen","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"10.1016\/j.jacl.2025.05.021_bib0035","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.021_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684182","article-title":"Case report: metreleptin treatment in a patient with a novel mutation for familial partial lipodystrophy type 3, presenting with uncontrolled diabetes and insulin resistance","volume":"12","author":"Lambadiari","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.021_bib0037","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Ca re"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:05:28Z","timestamp":1752577528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S1933287425003083"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.021","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}